1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Myasthenia Gravis: Epidemiology Forecast to 2028

Myasthenia Gravis: Epidemiology Forecast to 2028

  • September 2019
  • 27 pages
  • ID: 5825160
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Myasthenia Gravis: Epidemiology Forecast to 2028

Summary
Diagnosed prevalent cases of Myasthenia Gravis (MG) are forecast to increase in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) from 152,000 cases in 2018 to 169,000 cases in 2028, at an annual growth rate (AGR) of 1.07%. Myasthenia Gravis (MG) is characterized by weakness in eye, limb, and respiratory muscles. Patients have traditionally been divided into two categories: those with generalized disease and those presenting with disease limited to the eye muscles. Cases of Myasthenia Gravis (MG) have increased in recent years due to the growing and aging population.

The increase in prevalent cases of MG is related to the impact of effective treatment, improved diagnostic methods, and prolonged survival from disease.Risk factors for Myasthenia Gravis (MG) include female gender, autoimmune diseases, thymus diseases, and extrathymic cancers such as breast and lung cancers.

Smoking is suspected as a major risk factor for Myasthenia Gravis (MG), but there was no conclusive evidence until recently.

According to the September 2019 study by Apinyawasisuk and colleagues published in the American Journal of Ophthalmology, risk of ocular Myasthenia Gravis (MG) converting to generalized Myasthenia Gravis (MG) is higher in smokers compared to non-smokers.This was a retrospective cohort study of patients with ocular Myasthenia Gravis (MG) extracted from the database of the Neuroscience Laboratory in Thailand in the population ages 18 years and older.

Based on smoking history, odds of developing generalized Myasthenia Gravis (MG) from ocular Myasthenia Gravis (MG) were almost three times higher in smokers compared to non-smokers.

Generalized Myasthenia Gravis (MG) is the more severe form of the disease, affecting multiple organs, whereas ocular Myasthenia Gravis (MG) only causes weakness in the eye muscles. Most patients start with ocular Myasthenia Gravis (MG) and 12-80% of these cases develop into generalized Myasthenia Gravis (MG) at the later stages.

Further studies are required in different settings and countries to determine if the link between smoking and Myasthenia Gravis (MG) is genuine and also to explore the possible mechanism of action. As smoking is potentially a major risk factor, smoking cessation should be promoted to patients to prevent the risk of developing a more severe form of Myasthenia Gravis (MG).

Within the report “Myasthenia Gravis: Epidemiology Forecast to 2028” epidemiologists have utilized historical data obtained from peer-reviewed articles and population-based studies to build the forecast for the diagnosed prevalent cases of Myasthenia Gravis (MG) in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan). Epidemiologists applied the prevalence of Myasthenia Gravis (MG) drawn from the above source to each country’s population to calculate the number of estimated diagnosed prevalent cases for severity according to MGFA classifications respectively.

Scope
- The Myasthenia Gravis Epidemiology Report and Model provide an overview of the risk factors and global trends of Myasthenia Gravis (MG) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of MG segmented by age, sex, and severity according to Myasthenia Gravis Foundation of America (MGFA) classifications (Class I, Class II, Class III, Class IV, and Class V) in the 7MM. Additionally, the model includes a 10-year epidemiological forecast for the antibody status of MG.
- The MG epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
- The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy
The MG Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global MG market.
- Quantify patient populations in the global MG market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MG therapeutics in each of the markets covered.
- Understand magnitude of MG population by its severity.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($3995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Vagus Nerve Stimulators (VNS) - Medical Devices Pipeline Assessment, 2019

Vagus Nerve Stimulators (VNS) - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Vagus Nerve Stimulators (VNS) - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Vagus Nerve Stimulators (VNS) - Medical Devices Pipeline Assessment, 2019" provides an ...

Muscle Spasticity Global Clinical Trials Review, H2, 2019

Muscle Spasticity Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Muscle Spasticity Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Muscle Spasticity Global Clinical Trials Review, H2, 2019" provides an overview of Muscle Spasticity clinical trials ...

Multiple Sclerosis: Epidemiology Forecast to 2028

Multiple Sclerosis: Epidemiology Forecast to 2028

  • $ 3995
  • November 2019

Multiple Sclerosis: Epidemiology Forecast to 2028SummaryMultiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on